Emerging Markets Regulatory Tracker: Australia, India (Vol. 4 No. 14)
This article was originally published in PharmAsia News
Australia’s Therapeutic Goods Administration warns hip, knee and should implant firms to seek reclassification by June 30, while India’s health ministry wants urgent oversight of stem cells.